• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非典型垂体腺瘤的发病率、激素分布及术后随访

Incidence, hormonal distribution and postoperative follow up of atypical pituitary adenomas.

作者信息

Yildirim Ali Erdem, Divanlioglu Denizhan, Nacar Osman Arikan, Dursun Engin, Sahinoglu Mert, Unal Tuba, Belen Ahmed Deniz

机构信息

Ankara Numune Research and Education Hospital, Department of Neurosurgery, Ankara, Turkey.

出版信息

Turk Neurosurg. 2013;23(2):226-31. doi: 10.5137/1019-5149.JTN.6828-12.1.

DOI:10.5137/1019-5149.JTN.6828-12.1
PMID:23546909
Abstract

AIM

To assess the incidence, hormonal activity and postoperative follow up of the cases that are histopathologically diagnosed as atypical pituitary adenoma (APA) in our series.

MATERIAL AND METHODS

In this study, 13 atypical pituitary adenoma cases, by the WHO 2004 criteria, among the 146 pituitary adenoma patients operated on in our clinic between January 2009 and May 2012 by endoscopic endonasal transsphenoidal approach were included.

RESULTS

In histological studies, 133 cases were diagnosed as typical pituitary adenoma (91.1%) and 13 cases were APAs (8.9%) of which 10 were male (76.9%) and 3 were female (23.1%), ranged between 27 and 80 (mean 52.7) ages. Histopathological distribution of APAs was 9 nonsecretory adenomas (69.3%), 3 prolactinomas (23.1%) and 1 somatostatinoma (7.6%). Asymptomatic pituitary apoplexy was diagnosed in 4 cases (30.7%). Eleven cases of typical pituitary adenomas (8.2%) and 5 cases of the atypical pituitary adenomas (38.4%) were re-operated due to tumor recurrences.

CONCLUSION

Accurate histopathological examination shows that atypical pituitary adenoma is not a rare disease. Although it is not the only determinant, APAs are more prone to recurrence than typical adenomas. In our opinion, if total resection is not possible for the patients with APA, close postoperative follow up and additional curative therapy modalities are needed.

摘要

目的

评估我们系列中经组织病理学诊断为非典型垂体腺瘤(APA)病例的发病率、激素活性及术后随访情况。

材料与方法

本研究纳入了2009年1月至2012年5月间在我们诊所接受经鼻内镜经蝶窦手术的146例垂体腺瘤患者中,按照世界卫生组织2004年标准诊断的13例非典型垂体腺瘤病例。

结果

组织学研究中,133例被诊断为典型垂体腺瘤(91.1%),13例为非典型垂体腺瘤(8.9%),其中男性10例(76.9%),女性3例(23.1%),年龄在27至80岁之间(平均52.7岁)。非典型垂体腺瘤的组织病理学分布为9例无分泌性腺瘤(69.3%),3例催乳素瘤(23.1%)和1例生长抑素瘤(7.6%)。4例(30.7%)诊断为无症状垂体卒中。11例典型垂体腺瘤(8.2%)和5例非典型垂体腺瘤(38.4%)因肿瘤复发接受了再次手术。

结论

准确的组织病理学检查表明非典型垂体腺瘤并非罕见疾病。虽然不是唯一的决定因素,但非典型垂体腺瘤比典型腺瘤更容易复发。我们认为,对于非典型垂体腺瘤患者,如果无法进行全切,术后需要密切随访并采用其他治疗方式。

相似文献

1
Incidence, hormonal distribution and postoperative follow up of atypical pituitary adenomas.非典型垂体腺瘤的发病率、激素分布及术后随访
Turk Neurosurg. 2013;23(2):226-31. doi: 10.5137/1019-5149.JTN.6828-12.1.
2
Giant pituitary adenomas: surgical outcomes of 50 cases operated on by the endonasal endoscopic approach.巨大垂体腺瘤经鼻内镜手术 50 例的治疗效果分析。
World Neurosurg. 2014 Jul-Aug;82(1-2):e281-90. doi: 10.1016/j.wneu.2013.08.028. Epub 2013 Aug 29.
3
Fully endoscopic transsphenoidal surgery for functioning pituitary adenomas: a retrospective comparison with traditional transsphenoidal microsurgery in the same institution.功能性垂体腺瘤的全内镜经蝶窦手术:与同一机构传统经蝶窦显微手术的回顾性比较
Surg Neurol. 2009 Oct;72(4):336-40. doi: 10.1016/j.surneu.2009.04.012. Epub 2009 Jul 14.
4
The use of neuronavigation in transnasal transsphenoidal pituitary surgery.神经导航在经鼻蝶窦垂体手术中的应用。
Zentralbl Neurochir. 2005 Aug;66(3):126-32; discussion 132. doi: 10.1055/s-2005-836602.
5
Surgical management of selected pituitary macroadenomas using extended endoscopic endonasal transsphenoidal approach: early experience.采用扩展内镜经鼻蝶窦入路治疗特定垂体大腺瘤的手术治疗:早期经验。
Neurol India. 2013 Mar-Apr;61(2):122-30. doi: 10.4103/0028-3886.111114.
6
Fully endoscopic endonasal vs. transseptal transsphenoidal pituitary surgery.全内镜经鼻与经鼻中隔经蝶窦垂体手术对比
Minim Invasive Neurosurg. 2005 Dec;48(6):348-54. doi: 10.1055/s-2005-915635.
7
Endoscopic transsphenoidal treatment of hormonally active pituitary adenomas.内镜经蝶窦治疗有激素活性的垂体腺瘤。
Neuro Endocrinol Lett. 2007 Aug;28(4):438-44.
8
Tumor shrinkage after transsphenoidal surgery for nonfunctioning pituitary adenoma.经蝶窦手术治疗无功能垂体腺瘤后的肿瘤退缩。
J Neurosurg. 2013 Dec;119(6):1447-52. doi: 10.3171/2013.8.JNS13790. Epub 2013 Sep 27.
9
Transsphenoidal surgery assisted by a new guidance device: results of a series of 747 cases.新型引导装置辅助下的经蝶窦手术:747例系列病例结果
Clin Neurol Neurosurg. 2011 Oct;113(8):626-30. doi: 10.1016/j.clineuro.2011.04.010. Epub 2011 May 20.
10
Transsphenoidal adenomectomy for GH-, PRL- and ACTH-secreting pituitary tumours: outcome analysis in a series of 125 patients.经蝶窦垂体腺瘤切除术治疗生长激素、催乳素和促肾上腺皮质激素分泌型垂体瘤:125例患者的疗效分析
Neurol Sci. 2004 Dec;25(5):251-6. doi: 10.1007/s10072-004-0351-z.

引用本文的文献

1
The clinicopathological PANOMEN-3 classification predicts pituitary adenoma prognosis: a real-world retrospective single center study of a surgically treated cohort.临床病理PANOMEN-3分类可预测垂体腺瘤预后:一项对手术治疗队列的真实世界回顾性单中心研究。
Pituitary. 2025 Sep 7;28(5):97. doi: 10.1007/s11102-025-01562-9.
2
The Past, Present, and Future Statuses of Formerly Classified "Atypical Pituitary Adenomas": A Clinicopathological Assessment of 101 Cases in a Cohort of More than 1,000 Pure Endoscopically Treated Patients in Single Center.既往分类的“非典型垂体腺瘤”的过去、现在和未来状况:对单中心1000余例单纯内镜治疗患者队列中101例病例的临床病理评估
J Neurol Surg B Skull Base. 2021 Jul;82(Suppl 3):e94-e100. doi: 10.1055/s-0040-1702219. Epub 2020 Feb 20.
3
How to Classify the Pituitary Neuroendocrine Tumors (PitNET)s in 2020.2020年如何对垂体神经内分泌肿瘤(PitNET)进行分类。
Cancers (Basel). 2020 Feb 22;12(2):514. doi: 10.3390/cancers12020514.
4
A tale of pituitary adenomas: to NET or not to NET : Pituitary Society position statement.垂体腺瘤的故事:是神经内分泌肿瘤还是非神经内分泌肿瘤:垂体学会立场声明
Pituitary. 2019 Dec;22(6):569-573. doi: 10.1007/s11102-019-00988-2.
5
Prognostic factors of regrowth in nonfunctioning pituitary tumors.无功能垂体瘤复发的预后因素。
Pituitary. 2018 Apr;21(2):176-182. doi: 10.1007/s11102-017-0861-3.
6
Overview of the 2017 WHO Classification of Pituitary Tumors.《2017 年世界卫生组织垂体肿瘤分类概述》。
Endocr Pathol. 2017 Sep;28(3):228-243. doi: 10.1007/s12022-017-9498-z.
7
Analysis of Ki67, HMGA1, MDM2, and RB expression in nonfunctioning pituitary adenomas.无功能垂体腺瘤中Ki67、HMGA1、MDM2和RB表达的分析
J Neurooncol. 2017 Apr;132(2):199-206. doi: 10.1007/s11060-016-2365-9. Epub 2017 Mar 2.
8
The Predictive Value of Pathologic Features in Pituitary Adenoma and Correlation with Pituitary Adenoma Recurrence.垂体腺瘤病理特征的预测价值及其与垂体腺瘤复发的相关性
J Pathol Transl Med. 2016 Nov;50(6):419-425. doi: 10.4132/jptm.2016.06.30. Epub 2016 Oct 6.
9
Atypical pituitary adenomas: clinical characteristics and role of ki-67 and p53 in prognostic and therapeutic evaluation. A series of 50 patients.非典型垂体腺瘤:ki-67和p53在预后及治疗评估中的临床特征及作用。50例患者系列研究。
Neurosurg Rev. 2017 Jan;40(1):105-114. doi: 10.1007/s10143-016-0740-9. Epub 2016 May 23.
10
Histological criteria for atypical pituitary adenomas - data from the German pituitary adenoma registry suggests modifications.不典型垂体腺瘤的组织学标准——德国垂体腺瘤登记处的数据提示需要进行修正。
Acta Neuropathol Commun. 2015 Aug 19;3:50. doi: 10.1186/s40478-015-0229-8.